» Articles » PMID: 25879056

Ocular Complications of Inflammatory Bowel Disease

Overview
Publisher Wiley
Specialty Biology
Date 2015 Apr 17
PMID 25879056
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Though inflammatory bowel disease (IBD) has a specific predilection for the intestinal tract, it is a systemic inflammatory disorder affecting multiple organs, including the eye. Ocular complications directly related to IBD are categorized as primary and secondary. Primary complications are usually temporally associated with IBD exacerbations and tend to resolve with systemic treatment of the intestinal inflammation. These include keratopathy, episcleritis, and scleritis. Secondary complications arise from primary complications. Examples include cataract formation due to treatment with corticosteroids, scleromalacia due to scleritis, and dry eye due to hypovitaminosis A following gut resection. Some ocular manifestations of IBD can lead to significant visual morbidity and temporally associated complications can also be a herald of disease control. Furthermore, ocular manifestations of IBD can occasionally manifest before the usual intestinal manifestations, leading to an earlier diagnosis. Thus, it is important to understand the clinical presentation of possible ocular manifestations in order to initiate appropriate treatment and to help prevent significant visual morbidity.

Citing Articles

The causal impact of genetically predicted inflammatory bowel disease on extraintestinal manifestations: a mendelian randomization study.

Fan X, He A, Li K, Zhang M, Zhang Q, Xiao W BMC Gastroenterol. 2025; 25(1):135.

PMID: 40038580 PMC: 11881308. DOI: 10.1186/s12876-024-03566-4.


Ophthalmological manifestations in inflammatory bowel disease under the watchful eye of a gastroenterologist from a tertiary centre.

Lewandowski K, Kaniewska M, Karlowicz K, Wiecek M, Tulewicz-Marti E, Celmer P Prz Gastroenterol. 2025; 16(4):397-407.

PMID: 39810871 PMC: 11726220. DOI: 10.5114/pg.2024.144988.


Ocular Manifestations of IBD: Pathophysiology, Epidemiology, and Iatrogenic Associations of Emerging Treatment Strategies.

Richardson H, Yoon G, Moussa G, Kumar A, Harvey P Biomedicines. 2025; 12(12.

PMID: 39767762 PMC: 11673599. DOI: 10.3390/biomedicines12122856.


Inflammatory eye disease is a risk factor for future microscopic colitis: A nationwide population-based matched case control study.

Bergman D, Ebrahimi F, Sun J, Norin C, Mollazadegan K, Ludvigsson J United European Gastroenterol J. 2024; 12(8):1081-1090.

PMID: 38963730 PMC: 11485298. DOI: 10.1002/ueg2.12623.


Ophthalmological Manifestations in Inflammatory Bowel Diseases: Keep an Eye on It.

Migliorisi G, Vella G, Dal Buono A, Gabbiadini R, Busacca A, Loy L Cells. 2024; 13(2).

PMID: 38247834 PMC: 10814681. DOI: 10.3390/cells13020142.


References
1.
Cho J . The Nod2 gene in Crohn's disease: implications for future research into the genetics and immunology of Crohn's disease. Inflamm Bowel Dis. 2001; 7(3):271-5. DOI: 10.1097/00054725-200108000-00014. View

2.
Ardizzone S, Porro G . Biologic therapy for inflammatory bowel disease. Drugs. 2005; 65(16):2253-86. DOI: 10.2165/00003495-200565160-00002. View

3.
Kleessen B, Kroesen A, Buhr H, Blaut M . Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. Scand J Gastroenterol. 2002; 37(9):1034-41. DOI: 10.1080/003655202320378220. View

4.
Karban A, Eliakim R, Brant S . Genetics of inflammatory bowel disease. Isr Med Assoc J. 2002; 4(10):798-802. View

5.
Akpek E, Thorne J, Qazi F, Do D, Jabs D . Evaluation of patients with scleritis for systemic disease. Ophthalmology. 2004; 111(3):501-6. DOI: 10.1016/j.ophtha.2003.06.006. View